TruSight Oncology ctDNA is a pan-cancer next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling (CGP) from blood plasma.
The broad panel is designed with similar DNA content as its tissue counterparts (TruSight Oncology 500 and TruSight Oncology 500 High-Throughput), including key immuno-oncology (IO) biomarkers, making it ideal to utilize in conjunction with or without precious tissue samples.
Enable Comprehensive Genomic Profiling from Plasma
Implement In-house CGP with an Integrated Workflow
Achieve Confidence in Results
Unlock Liquid Biopsy, Including Valuable IO Insights
Innovations in molecular assays enable comprehensive, precise analysis of cell-free DNA.
Read Application Spotlight
All three TruSight Oncology 500 assays are designed to identify key biomarkers in guidelines and clinical trials.
Assess key cancer biomarkers from FFPE tumor tissue with the TruSight Oncology 500 Assay.
Batch up to 192 samples at a time while using the same biomarkers and tissue type as the TruSight Oncology 500 assay.
Analyze circulating tumor DNA from plasma with the TruSight Oncology 500 ctDNA assay.
| Instrument | Recommended Number of Samples | Read Length |
|---|---|---|
| NovaSeq 6000 System | 24 samples per run (S4 flow cell), 800M paired-end reads, 35,000x coverage | 2 × 150 bp |
| NovaSeq 6000 System | 8 samples per run (S2 flow cell), 800M paired-end reads, 35,000x coverage | 2 × 150 bp |
| TruSight Oncology 500 ctDNA | TruSight Oncology 500 | TruSight Oncology 500 High-Throughput | |
|---|---|---|---|
| Cancer Type | Pan-Cancer | Pan-Cancer | Pan-Cancer |
| Content Specifications | Targeted selection of 523 genes (full coding sequence) for a total of 1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Immuno-oncology Biomarker Coverage: TMB and MSI* |
Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical Trials Coverage: Over 1,000 clinical trials • Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1* • TruSight Oncology 500 HRD** kit content includes coverage of ~25,000 SNP's to assess homologous recombination deficiency through a comprehensive genomic instability score (LOH+TAI+LST), powered by Myriad Genetics • TruSight Oncology 500 HRD** is an optional add-on kit to TruSight Oncology 500 **Not available in Japan |
Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical Trials Coverage: Over 1,000 clinical trials • Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1* |
| Hands-On Time | Manual: ~10.5 hrs Automated: N/A |
Manual: ~10.5 hrs Automated: ~2.5 hrs (TruSight Oncology 500 only) |
Manual: ~10.5 hrs Automated: ~2.5 hrs |
| Method | Target Enrichment, Target Enrichment, Targeted DNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing |
| Nucleic Acid Type | DNA | RNA, DNA | RNA, DNA |
| Specialized Sample Types | Blood, Circulating Tumor DNA | FFPE Tissue | FFPE Tissue |
| Species Category | Human | Human | Human |
| System Compatibility | NovaSeq 6000 | NextSeq 500, NextSeq 550, NextSeq 550Dx in Research Mode | NovaSeq 6000 |
| Technology | Sequencing | Sequencing | Sequencing |
| Variant Class | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Somatic Variants | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants |
* Based on PierianDx Clinical Genomics Knowledgebase, as of March 2020.
Simplifying the process to identify applicable variants in oncology samples
Brochure | PDF 2 MB
Liquid Biopsy and NGS: Driving translational clinical research to the next level
Application Note | PDF < 1 MB
Technical Note | PDF | 2 versions
Technical Note | PDF | 2 versions
TruSight Oncology 500 ctDNA Gene List
product_file | EXCEL < 1 MB
Data analysis and reporting for the TruSight Oncology 500 portfolio
Product Information Sheet | PDF 1 MB
Data Sheet | PDF | 7 versions
TruSight Oncology 500 ctDNA Support Documentation
DRAGEN TruSight Oncology 500 ctDNA Analysis Software v1.2 on ICA Documentation
TruSight Oncology 500 ctDNA Checklist Documentation
DRAGEN Analysis Workflows Product Documentation
DRAGEN TruSight Oncology 500 ctDNA Analysis Software v2.1.1 on ICA Documentation
TruSight Oncology 500 ctDNA Consumables & Equipment Documentation
TruSight Oncology 500 ctDNA Local App Documentation
DRAGEN TruSight Oncology 500 ctDNA Analysis Software v1.2 Documentation
DRAGEN TruSight Oncology 500 ctDNA Local Analysis Software v2.1 Documentation
DRAGEN TruSight Oncology 500 ctDNA v1.1 Local Analysis Software Documentation
The NovaSeq Xp workflow enables labs to load libraries directly into each lane of a NovaSeq 6000 System flow cell, without additional instrumentation.
A high-performing, fast, and integrated workflow for sensitive applications such as human whole-genome sequencing.
Rapid library preparation from a broad range of sample types for studying the coding and non-coding transcriptome with exceptional study flexibility.
Reagent kits for the NovaSeq 6000 system provide ready-to-use cartridge-based reagents for cluster generation and SBS.
A simple, scalable, cost-effective, rapid single-day solution for analyzing the coding transcriptome leveraging as little as 25 ng input of standard (non-degraded) RNA.
Enabling comprehensive genomic profiling from FFPE samples, with added flexibility to batch up to 192 samples per flow cell.
